SILVER SPRING, Md., Oct. 23, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") today announced that Clotamin® is now available at CVS.com. Clotamin® is a unique and complete multivitamin formulated without vitamin k to meet the special nutritional needs of people taking blood thinning medications (anticoagulants) such as Warfarin. Because it does not contain vitamin k, Clotamin® can be taken with Warfarin. Warfarin is the most prescribed blood thinning medication in North America and is also known under the brand names of Coumadin®, Jantoven®, Marevan®, and Waran®. Warfarin therapy reduces the formation of blood clots, which is important in the prevention of heart attacks, strokes, and blockage of major veins and arteries.
Vitamin k is a common ingredient in most multivitamins on the market and can thicken blood and interfere with Warfarin therapy. People who are prescribed blood thinners are required to follow strict nutritional guidelines in order to maintain healthy International Normalized Ratio (INR) levels. The most significant of these guidelines is the consumption of a consistent amount of vitamin k in their diet. Clotamin includes Biotin to prevent hair loss associated with Warfarin as well as a full b complex to boost energy.
To find Clotamin® at CVS.com, follow this link http://www.cvs.com/search/_/N-0?searchTerm=clotamin&pt=global
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Pharmagen, Inc.